title: Successful management of lipid-lowering programs.
abstract: Health improvement programs must today face the hurdle of demonstrating their value to the business professionals in managed care organizations. These individuals have vast fiscal responsibilities but often lack a medical background. It is imperative that program advocates not only identify these key decision makers, but present an argument for program adoption by using data these decision-makers are most familiar with: grounded, quantitative results. This tactic can enhance the likelihood of a program being implemented. To validate the proposed program to the MCO business sector, it must address a disease or condition that is characterized by wide variation in physician practice, high cost, high volume, and an evidence base that supports the proposed intervention.
authors.forename: A T
authors.initials: AT
authors.lastname: Wright
mesh_terms: D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D003362:Cost-Benefit Analysis; D003657:Decision Making; D019468:Disease Management; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D008329:Managed Care Programs / Q000592:standards*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014481:United States
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL